(@clinpgx.org)

Updates to the CPIC Database and API We want to inform everyone of some things that are changing (and some things that are not) in the CPIC database and API. CPIC and ClinPGx CPIC is now part of ClinPGx. The standalone CPIC site will retire soon, but all its content will move to ClinPGx. Visiting cpicpgx.org will redirect you to the corresponding ClinPGx page. We’re not planning any changes to the CPIC database or API. The database stays on GitHub at the releases page, and the API remains at https://api.cpicpgx.org. If we need

ClinPGx Blog: Updates to the CPIC Database and API

04.03.2026 17:41 👍 0 🔁 0 💬 0 📌 0

CPIC is moving to the ClinPGx website The Clinical Pharmacogenetics Implementation Consortium is moving to the ClinPGx website. All CPIC information will still be available in a similar format. All current and published CPIC URLs should re-direct to equivalent pages on the ClinPGx website, so existing bookmarks and links should not break. We plan for CPIC URLs to re-direct starting March 9, 2026. The website move does not affect the CPIC DB or API. As always, if you experience any issues, please let us know at feedback@clinpgx.org.

ClinPGx Blog: CPIC is moving to the ClinPGx website

02.03.2026 14:00 👍 0 🔁 0 💬 0 📌 0

New and Updated Antipsychotics Pathways CPIC is currently evaluating evidence on antipsychotics and CYP2D6, CYP3A4 and CYP2C19 for the development of guidelines. To support this ClinPGx curators have expanded our set of antipsychotics pathways; updating and developing some of our in progress pathways and curating some new ones.

ClinPGx Blog: New and Updated Antipsychotics Pathways

25.02.2026 21:48 👍 0 🔁 0 💬 0 📌 0

CPIC Guideline Update for TPMT, NUDT15 and Thiopurines The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update has been published in Clinical Pharmacology and Therapeutics (PMID:41618934). The guideline contains multiple updates to the previous recommendations for adjusting the starting doses of azathioprine, mercaptopurine and thioguanine according to the combination of TPMT and NUDT15 phenotypes derived from genotypes and the specific indication (i.e. malignant

ClinPGx Blog: CPIC Guideline Update for TPMT, NUDT15 and Thiopurines

06.02.2026 17:39 👍 0 🔁 0 💬 0 📌 0

New PharmCAT release Highlights of the latest releases (v3.1.0- v3.1.1) are: * CPIC function and phenotype assignments are used to provide genotype-level guidance from all sources including DPWG and FDA. For a detailed blog see, Genotype-Phenotype Mapping for Guideline and Drug Label Curation. * Allele definitions are up to date to PharmVar’s Version 6.2.17.2, which adds new alleles for NAT2, CYP2C19, CYP2C9, SLCO1B1. * Recommendation updates (see full list of gene and drugs included in PharmCAT) * Addition

ClinPGx Blog: New PharmCAT release

20.11.2025 01:16 👍 0 🔁 0 💬 0 📌 0

Genotype-Phenotype Mapping for Guideline and Drug Label Curation ClinPGx now uses CPIC/ClinPGx allele function and phenotype mappings and terms for guideline and drug label curation, including the interactive genotype picker tools on DPWG guideline annotation pages. If a DPWG guideline gene is not a CPIC gene, then we will continue to use DPWG mappings based on documents previously downloaded from the KNMP website. The DPWG terms and mapping largely agree with CPIC/ClinPGx across genes, but exceptions are noted on the DPWG mappings page. We will also continue

ClinPGx Blog: Genotype-Phenotype Mapping for Guideline and Drug Label Curation

21.10.2025 23:28 👍 0 🔁 0 💬 0 📌 0

Updated FDA-approved label for Xeloda (capecitabine) The FDA-approved label for Xeloda (capecitabine) was updated a week ago to include a boxed warning regarding adverse reactions in patients with complete DPD deficiency and to "Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary." This language is new. The previous version of the label recommended against using the drug "in patients known to have certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficie

ClinPGx Blog: Updated FDA-approved label for Xeloda (capecitabine)

10.10.2025 20:49 👍 0 🔁 0 💬 0 📌 0

CPIC Guideline for NAT2 Genotype and Hydralazline Therapy The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension and heart failure, into inactive metabolites. This is the first CPIC guideline for NAT2 (N-acetyltransferase 2). From the guideline: "NAT2 poor metabol

ClinPGx Blog: CPIC Guideline for NAT2 Genotype and Hydralazline Therapy

25.09.2025 17:36 👍 0 🔁 0 💬 0 📌 0

ClinGen Pharmacogenomics Interpretation Committee Publication on Survey Findings We are excited to announce the publication of Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities (PMID: 40662343) by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC) in Genetics in Medicine. This publication covers the results of the PGxIC’s two needs assessment surveys targeting both the pharmacogenomics and genomic medicine communities, and can be read at this link free of charge until October 2, 2025. We thank all of

ClinPGx Blog: ClinGen Pharmacogenomics Interpretation Committee Publication on Survey Findings

19.08.2025 18:17 👍 0 🔁 0 💬 0 📌 0

In Press: Survey Findings on Integrating Pharmacogenomics into Genomic Medicine We’re excited to announce that our latest paper, titled “Towards an Integrated Resource for Pharmacogenomics (PGx): Survey Findings from the Genomic Medicine Communities,” is now in press in Genetics in Medicine! This work, conducted by the ClinGen Pharmacogenomics Interpretation Committee (PGxIC, formerly the PGx Working Group), presents findings from two community surveys that gathered perspectives from over 500 participants across the PGx and genomic medicine communities. The goal of the sur

ClinPGx Blog: In Press: Survey Findings on Integrating Pharmacogenomics into Genomic Medicine. Read more here: https://blog.clinpgx.org/in-press-survey-findings-on-integrating-pharmanomics-into-ge/

14.07.2025 05:07 👍 0 🔁 0 💬 0 📌 0

PharmGKB is moving to ClinPGx Nearly two years ago, we introduced the vision for ClinPGx to integrate the PharmGKB, CPIC and PharmCAT projects into a unified resource. In June 2024, we launched the ClinPGx blog and held the first ClinPGx Meeting. We are excited to announce that over the coming weeks, PharmGKB will officially become ClinPGx. Once the new ClinPGx website debuts, there will be a brief period where both websites will co-exist. At the end of this period, PharmGKB URLs will automatically redirect users to the eq

ClinPGx Blog: PharmGKB is moving to ClinPGx. Read more here: https://blog.clinpgx.org/clinpgx/

10.07.2025 04:50 👍 0 🔁 0 💬 0 📌 0

PharmGKB User Survey PharmGKB is conducting a survey designed to gather user feedback to enhance our content, features and tools. Your insights are essential as PharmGKB transitions to ClinPGx this summer and we prepare our next grant application to support our ongoing project. We would be incredibly grateful for your thoughts on the relevance and value of the PharmGKB website. The survey is designed to be quick and easy, consisting of two parts: (1) a brief section that takes approximately 1 minute to complete, an

ClinPGx Blog: PharmGKB User Survey. Read more here: https://blog.clinpgx.org/pharmgkb-survey/

09.06.2025 12:00 👍 0 🔁 0 💬 0 📌 0

Recent Updates to PharmGKB’s Genotype Selection Interface (GSI) Tool We are excited to announce that we have partnered with Dr. Emily Cicali on behalf of The University of Florida Health Precision Medicine Program to incorporate the information presented in the PROPTM pharmacogenetics calculator into the GSI. Users can select from a list of concomitant medications that are either strong or moderate CYP2D6 inhibitors to account for CYP2D6 phenoconversion. Additionally, the following updates have been made: * Users can now enter gene phenotypes as input as well

ClinPGx Blog: Recent Updates to PharmGKB’s Genotype Selection Interface (GSI) Tool. Read more here: https://blog.clinpgx.org/recent-updates-to-pharmgkbs-genotype-selection-interface-gsi-tool/

15.05.2025 16:04 👍 1 🔁 0 💬 0 📌 0

Latest posts by @clinpgx.org